GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Syntara Ltd (FRA:UUDA) » Definitions » Notes Receivable

Syntara (FRA:UUDA) Notes Receivable : €0.00 Mil (As of Dec. 2024)


View and export this data going back to 2006. Start your Free Trial

What is Syntara Notes Receivable?

Syntara's Notes Receivable for the quarter that ended in Dec. 2024 was €0.00 Mil.


Syntara Notes Receivable Historical Data

The historical data trend for Syntara's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Syntara Notes Receivable Chart

Syntara Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
Notes Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Syntara Semi-Annual Data
Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Syntara Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.


Syntara Notes Receivable Related Terms

Thank you for viewing the detailed overview of Syntara's Notes Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


Syntara Business Description

Traded in Other Exchanges
Address
20 Rodborough Road, Unit 2, Frenchs Forest, Sydney, NSW, AUS, 2086
Syntara Ltd is a clinical-stage drug development company working to bring new and life-changing treatments to patients in need. It is targeting extracellular matrix dysfunction with its expertise in amine oxidase chemistry and other technologies to develop novel medicines for blood cancers and conditions linked to inflammation and fibrosis. The company has various drug candidates in its pipeline such as SNT-5505, SNT-4728, SNT-5382, and SNT-8370 as a potential treatment for cancer, skin scarring, and neuroinflammation.

Syntara Headlines

No Headlines